Stock Ratings / Health Care / LONA / options

TIL (51) IMA (24) CRBU (43) INMB (45) ⌘ Pro Terminal →

LeonaBio Inc. (LONA) Options Positioning, Max Pain & Unusual Sweeps

$4.91 -1.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

LeonaBio Inc. (LONA) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $46.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LONA)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (LONA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for LONA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LONA)

✓Walkthrough of LONA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LONA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.04%▼ DESCENDING CHANNEL

2026-10-30O $4.89H $5.14L $4.76C $4.91VOL 43.1K

RES: $6.50SUP: $0.37SMA50: $6.05SMA200: $7.51

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LONA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LONA Butterfly Map → + Track LONA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LONA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LONA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LONA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LONA)

Health Care Rank #587 of 1016 ⚔️ TIL vs LONA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LONA vs. TIL, IMA, CRBU, INMB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LeonaBio Inc. (LONA) ranks #587 by composite RQD confidence (42/100, grade D-) and #761 by equity capitalization ($46.3M). Within this direct 5-issuer industry benchmark cohort, LONA leads on earnings valuation at N/A trailing P/E, while LONA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with LONA at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LONA ACTIVE LeonaBio Inc.	D-	42/100	—	—	-35.0%	-1.01%	$46.3M	Benchmark Subject
TIL Instil Bio Inc.	D	51/100	—	—	-35.0%	+0.52%	$46.3M	/til-vs-lona →
IMA ImageneBio Inc.	E	24/100	—	—	-35.0%	-3.57%	$46.0M	/ima-vs-lona →
CRBU Caribou Biosciences Inc.	D-	43/100	—	—	-35.0%	-9.07%	$47.7M	/crbu-vs-lona →
INMB INmune Bio Inc.	D	45/100	—	—	-35.0%	+4.58%	$44.4M	/inmb-vs-lona →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001620463

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LeonaBio Inc. (LONA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$106.0M, operating cash flow of -$45.7M, and free cash flow of -$45.7M (+53.0% YoY). On the balance sheet, LONA closed FY2025 with $92.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$106.0M	-$45.7M	-$45.7M	$92.2M	—
FY2024 (FY)	2024-12-31	$0	-$97.0M	-$97.2M	-$97.2M	$58.8M	—
FY2023 (FY)	2023-12-31	$0	-$117.7M	-$100.8M	-$100.8M	—	—

3. LONA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LONA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, LeonaBio Inc. (NASDAQ: LONA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $4.91 (-1.01% 1D, market cap $46.3M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LONA ranks #587 in composite RQD confidence.

How does LONA compare to TIL and IMA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LONA carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TIL (Instil Bio Inc.) holds a D grade (51/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and IMA (ImageneBio Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $46.0M). Among the 5-stock peer group, LONA leads on earnings multiple (N/A) while LONA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LONA?

Per LONA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001620463), LeonaBio Inc. generated $0 in revenue, -$106.0M in net income, and -$45.7M in free cash flow against $92.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LONA trading relative to its 50-day, 200-day, and 52-week technical levels?

LONA last traded at $4.91 (-1.01% on volume of 162,059 shares), positioning the stock -18.84% below its 50-day simple moving average ($6.05) and -34.62% below its 200-day simple moving average ($7.51). Across its 52-week range of $2.21 to $14.21, LONA sits at the 22.5% percentile with a 14-day RSI of 43.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.30 to $5.52).